**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTAL INFORMATION:** Technology description follows.

**CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis**

**Description of Technology:** The innate immune system is the first line of host defense against invading pathogens. Lipopolysaccharides (LPS), present in gram-negative bacteria membranes, cause strong immune responses following detection by the Toll-like receptor 4 (TLR4) on immune cells. This detection results in the release of pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin-6, and interferon gamma, to assist with clearance of the infectious insult. In parallel, interleukin-10 (IL–10), an anti-inflammatory cytokine, is induced to limit the immune response. This is because unchecked immune activation leads to a more severe immunopathology, such as septic shock and subsequently death. Current therapies to treat sepsis are ineffective, and clinical trials based on neutralization of specific inflammatory cytokines have failed.

The inventors, listed below, have discovered that CD300b is a LPS binding receptor. This interaction results in a reduced IL–10 production, leading to an amplification of lethal inflammation. In vitro, anti-CD300b antibodies block LPS binding to CD300b, stopping association with TLR4 and CD14 and increases IL–10 levels. In vivo, administration of anti-CD300b antibodies protects animals from septic shock, due to a reduced level of pro-inflammatory cytokines but subsequent increase in the anti-inflammatory cytokine, IL–10. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

**Potential Commercial Applications:**

As a means of treating endotoxemia and septic peritonitis.

**Competitive Advantages:** No current therapeutics are available to treat septic shock.

**Development Stage:** Pre-clinical.

**Inventors:** John E. Coligan, NIAID, NIH
Oliver H. Voss, NIAID, NIH
Konrad Krzewska, NIAID, NIH

**Publications:** Voss, Oliver H., et al. "Lipopolysaccharide-induced CD300b receptor binding to toll-like receptor 4 alters signaling to drive cytokine responses that enhance septic shock." Immunity 44.6 (2016): 1365–1378.


**Licensing Contact:** Chris Kornak, 240–627–3705, chris.kornak@nih.gov.

**Collaborative Research Opportunity:** The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further co-develop CD300b antagonists. For collaboration opportunities, please contact Chris Kornak, 240–627–3705, chris.kornak@nih.gov.


Suzanne Frishie,
Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2017–03452 Filed 2–22–17; 8:45 am]

BILLING CODE 4140–01–P
Activities, Room # 3G41B, National Institutes of Health/NIADD, 5601 Fishers Lane, MSC0823, Bethesda, MD 20892–9823, (240) 669–5068, zhuxing.li@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)


Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[F.R. Doc. 2017–03531 Filed 2–22–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention: Notice of Meeting

Pursuant to Pub. L. 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention Drug Testing Advisory Board (DTAB) will meet in person and via web conference on March 20, 2017, from 9:00 a.m. to 5:00 p.m. EDT and March 21, 2017 from 9:00 a.m. to 2:00 p.m. EDT.

The Board will meet in open session on March 20, 2017, from 9:00 a.m. to 2:00 p.m., to provide updates on the Mandatory Guidelines for Federal Workplace Drug Testing Programs, provide data on hair testing programs currently in use in the private sector, research data on marijuana edibles, and the most current data from Quest Diagnostics Drug Testing Index.

The board will meet in closed session on March 20, 2017, from 2:00 p.m. to 5:00 p.m. EDT and on March 21, 2017, from 9:00 a.m. to 2:00 p.m. EDT to hear about current confidential practices in the hair testing industry, and to discuss proposals for the Oral Fluid Mandatory Guidelines for Federal Workplace Drug Testing Programs. Therefore, these portions of the meeting are closed to the public as determined by the Administrator, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d).

Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees Web site, http://www.samhsa.gov/about-us/advisory-councils/drug-testing-advisory-board-dtab, or by contacting Brian Makela.

Committee Name: Substance Abuse and Mental Health Services Administration’s Center for Substance Abuse Prevention Drug Testing Advisory Board.

Dates/Time/Type: March 20, 2016, from 9:00 a.m. to 2:00 p.m., EDT: OPEN. March 20, 2016, from 2:00 p.m. to 5:00 p.m., EDT: CLOSED. March 21, 2016, from 9:00 a.m. to 2:00 p.m., EDT: CLOSED.

Place: Parklawn Building, Room 5W07, 5600 Fishers Lane, Rockville, Maryland 20857.

Contact: Brian Makela, Division of Workplace Programs, 5600 Fishers Lane, Room 16N02B, Rockville, Maryland 20857, Telephone: 240–276–2600, Fax: 240–276–2610, Email: brian.makela@samhsa.hhs.gov.

Brian Makela,
Chemist, Substance Abuse and Mental Health Services Administration.

[F.R. Doc. 2017–03480 Filed 2–22–17; 8:45 am]
BILLING CODE 4162–20–P

DEPARTMENT OF HOMELAND SECURITY

U.S. Citizenship and Immigration Services

OMB Control Number 1615—NEW

Agency Information Collection Activities: Independent Evaluation of the Systematic Alien Verification for Entitlements (SAVE) Program, Form G–1503; New Collection


ACTION: 60-Day Notice.

SUMMARY: The Department of Homeland Security (DHS), U.S. Citizenship and Immigration (USCIS) invites the general public and other Federal agencies to comment upon this proposed new collection of information. In accordance with the Paperwork Reduction Act (PRA) of 1995, the information collection notice is published in the Federal Register to obtain comments regarding the nature of the information collection, the categories of respondents, the estimated burden (i.e., the time, effort, and resources used by the respondents to respond), the estimated cost to the respondent, and the actual information collection instruments.

DATES: Comments are encouraged and will be accepted for 60 days until April 24, 2017.

ADDRESSES: All submissions received must include the OMB Control Number 1615–NEW in the body of the letter, the agency name and Docket ID USCIS–2016–0007. To avoid duplicate submissions, please use only one of the following methods to submit comments:


(2) Mail. Submit written comments to DHS, USCIS, Office of Policy and Strategy, Chief, Regulatory Coordination Division, 20 Massachusetts Avenue NW., Washington, DC 20529–2140.

FOR FURTHER INFORMATION CONTACT: USCIS, Office of Policy and Strategy, Regulatory Coordination Division, Samantha Deshommes, Chief, 20 Massachusetts Avenue NW., Washington, DC 20529–2140, telephone number 202–272–8337 (This is not a toll-free number. Comments are not accepted via telephone message). Please note contact information provided here is solely for questions regarding this notice. It is not for individual case status inquiries. Applicants seeking information about the status of their individual cases can check Case Status Online, available at the USCIS Web site at http://www.uscis.gov, or call the USCIS National Customer Service Center at 800–375–5283 (TTY 800–767–1833).

SUPPLEMENTARY INFORMATION:

Comments

You may access the information collection instrument with instructions, or additional information by visiting the Federal eRulemaking Portal site at: http://www.regulations.gov and enter USCIS–2016–0007 in the search box. Regardless of the method used for submitting comments or material, all submissions will be posted, without change, to the Federal eRulemaking Portal at http://www.regulations.gov, and will include any personal information you provide. Therefore, submitting this information makes it public. You may wish to consider limiting the amount of personal information that you provide in any voluntary submission you make to DHS. DHS may withhold information provided in comments from public viewing that it determines may impact the privacy of an individual or is offensive. For additional information, please read the Privacy Act notice that is available via the link in the footer of http://www.regulations.gov.

Written comments and suggestions from the public and affected agencies should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary